Physician profile
Siddharth Singh
NPI 1316137136
$6,567.83
in general payments reported to CMS, 2019-2025
10 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,730 · 2021: $63.40 · 2022: $344 · 2023: $3,066 · 2024: $95.00 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Travel and Lodging: $1,175 · Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Travel and Lodging | $1,174.83 |
| Food and Beverage | $755.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Canon Medical Systems USA, INC. | $2,500.00 | 2023 | Diagnostic Ultrasound System |
| Abbott Laboratories | $2,097.43 | 2019-2025 | Triclip, Ensite |
| Edwards Lifesciences Corporation | $1,361.85 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Inari Medical, INC. | $207.04 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Actelion Pharmaceuticals US, INC. | $157.64 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.90 | 2023 | Camzyos |
| Abiomed | $80.80 | 2024 | Impella |
| Amgen INC. | $21.90 | 2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $19.27 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siddharth Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.